Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer

Mythili Shastry a, Saya Jacob b, Hope S. Rugo b, Erika Hamilton a,c,*

a Sarah Cannon Research Institute, Nashville, TN, USA
b University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA
c Tennessee Oncology, Nashville, TN, USA

ARTICLE INFO

Keywords:
Antibody drug conjugate (ADC)
Trophoblast cell surface antigen-2 (TROP-2)
Sacituzumab govitecan
Datopotamab deruxtecan
Metastatic breast cancer

ABSTRACT

Antibody drug conjugates (ADCs) combine the potent cytotoxicity of chemotherapy with the antigen-specific targeted approach of antibodies into one single molecule. Trophoblast cell surface antigen 2 (TROP-2) is a transmembrane glycoprotein involved in calcium signal transduction and is expressed in multiple tumor types. TROP-2 expression is higher in HER2-negative breast tumors (HR+/HER2-) and is associated with worse survival. Sacituzumab govitecan (SG) is a first-in-class TROP-2-directed ADC with an anti-TROP-2 antibody conjugated to SN-38, a topoisomerase inhibitor via a hydrolysable linker. This hydrolysable linker permits intracellular and extracellular release of the membrane permeable payload enabling the “bystander effect” contributing to the efficacy of this agent. There was significant improvement in progression free survival (PFS) and overall survival (OS) with SG versus chemotherapy in pretreated metastatic triple negative breast cancer (TNBC), resulting in regulatory approval. Common adverse events (AE) reported were neutropenia and diarrhea. SG also demonstrated clinical activity versus chemotherapy in a phase III trial of HR+/HER2-metastatic breast cancer (MBC) and is under evaluation in first-line metastatic and early stage TNBC as well. Datopotamab deruxtecan (Dato-DXd) is a TROP-2 ADC that differs from SG in that it has a cleavable tetrapeptide linker and a more potent topoisomerase inhibitor payload. This construct is highly stable in circulation with a longer half-life than SG, and undergoes cleavage in presence of intracellular lysosomal proteases. Dato-DXd demonstrated preliminary efficacy in unselected metastatic TNBC, with common AEs of low-grade nausea and stomatitis. Dato-DXd is being investigated in phase III studies in metastatic TNBC and HR+/HER2- MBC. These novel TROP-2 ADCs have the potential to deliver enhanced efficacy with reduced toxicity in MBC and possibly in early stage breast cancer (EBC).

1. Introduction to antibody drug conjugates

The identification of oncogenic drivers in various cancers paved the way for development of targeted therapies with monoclonal antibodies. These biological agents had the ability to precisely target tumors harboring the specific biomarker/altered in contrast to the indiscriminate cell death caused by chemotherapy. In the past couple of decades, there have been major efforts to combine the specificity of monoclonal antibodies with potency of chemotherapy to generate antibody drug conjugates (ADCs). ADCs utilize target-specific antibodies as vehicles to deliver a potent cytotoxic to tumor cells while sparing healthy cells, thus limiting toxicity. This concept harks back to a theory proposed by Paul Ehrlich in the 1900s, where he envisioned a drug that could be delivered to the target cell via a “magic bullet” while sparing...
normal tissue [1]. The challenge in realizing this goal is underscored by the decades of research that finally culminated in the regulatory approval of the first ADC gemtuzumab ozogamicin (Mylotarg®) in 2000.

1.1. Components of an ADC

Antibody drug conjugates have 3 core components: a monoclonal antibody (MAb) targeting a specific tumor antigen, a cytotoxic payload, and a chemical linker connecting them. The basic mechanism involves binding of the antibody to the tumor antigen on the cell surface, followed by internalization of the ADC and lysosomal degradation. This results in release of the active cytotoxic agent into the cytoplasm which results in tumor cell death. Some ADCs also induce antibody dependent cellular cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC) contributing to the antitumor efficacy of these agents [2].

The foremost consideration for design of the ADC is the selection of a tumor-specific antigen accessible to antibody binding on the tumor cell surface. The overexpression of the target antigen on tumor vs healthy cells is key to precise ADC delivery resulting in high specificity as well as efficacy. Targets that are oncogenic drivers are less likely to be downregulated as a mechanism of drug resistance and may thus be a better choice as the antigen to be targeted by ADCs.

Payloads in ADCs need to have high potency (nano-picomolar range) to precipitate cell lysis once delivered into the tumor, since a very small fraction of the ADC (~0.1%) actually reaches the tumor tissue [3,4]. The potency of these payloads is often the source of the toxicity associated with ADCs and some of these toxicities are usually characteristic of the class of payload (ex: peripheral neuropathy is attributed to microtubule inhibitors like DM1, DM4, MMAE) [5]. Furthermore, payload drugs must be impervious to efflux proteins in order to remain in the target tumor cells.

The linker is attached to the MAb at a specific number of sites depending on the conjugation chemistry utilized. This linker has a dual role; one is to avoid the premature release of the payload which leads to unwanted systemic toxicity [6] and the second is to enable efficient release of payload once inside the tumor cell [7]. Cleavable linkers are designed to release the payload of the ADC under acidic conditions or in presence of proteolytic enzymes; examples include mirvetuximab soravtansine and sacituzumab govitecan. ADCs with cleavable linkers tend to have varying degrees of stability in circulation and may degrade over time in the plasma [6]. Non-cleavable linkers on the other hand, are in stable in plasma and release the payload only after intracellular lysosomal degradation of the ADC [6]. Trastuzumab emtansine (T-DM1) is the best-known example.

1.2. Mechanism of action of an ADC

ADCs essentially deliver a cytotoxic agent to tumors with high selectivity, minimizing systemic exposure and thereby toxicity, thus improving therapeutic index. Binding of the ADC to a receptor on the cancer cell results in a complex that is internalized via clathrin- or caveolae-mediated endocytosis or via pinocytosis [8,9]. This internalization leads to an inward budding resulting in endosome formation before fusing with lysosomes [10]. Once inside the lysosomes or endosomes, acidic, proteolytic or redox conditions result in release of the payload from the antibody. The payload then diffuses into the cytoplasm and acts on the target substrates precipitating cell death.

1.2.1. Bystander effect

Some payloads have high membrane permeability and can diffuse out into neighboring tumor cells that may or may not express the target antigen and promote their death as well. This phenomenon is known as “bystander effect”. Bystander killing is influenced by extent of ADC internalization, presence of cleavable or non-cleavable linker, and the nature of the cytotoxic payload [11]. Recent studies indicate that internalization and intracellular linker cleavage may not be essential for ADC processing in all cases. After binding of the ADC to the target antigen, but before internalization, ADCs can be cleaved by extracellular enzymes (like Cathepsin B) released by the surrounding tumor cells and tumor associated macrophages, releasing the cytotoxic payload that penetrates surrounding “bystander” cells resulting in cell death [12].

1.2.2. Effect of payload

Payloads are usually small molecule agents that may be too toxic as stand-alone drugs but are potent enough to cause cell lysis at IC50 in the nano-picomolar range. Payloads utilized in current ADCs can be broadly categorized as agents that 1) disrupt microtubule polymerization ex: maytansoids like DM1 and DM4, auristatin based agents (MMAE, MMAF), 2) DNA damaging agents like calicheamicin or duocarmycin, or 3) topoisomerase I inhibitors (SN-38 and derivatives or DxD) [13].

The drug to antibody ratio (DAR) is the number of cytotoxic payloads loaded onto the antibody and is an important feature that may influence the efficacy of an ADC. A higher DAR does not necessarily imply greater efficacy but a low DAR may impact efficacy [14].

Of the dozens of ADCs in clinical development for cancer, three ADCs have FDA approval for treatment of metastatic breast cancer (MBC); sacituzumab govitecan - a Trophoblast agent-2 (TROP-2) targeting ADC and two HER2-directed ADCs - T-DM1 and trastuzumab deruxtecan (T-Dx). [15].

1.3. TROP-2 protein

TROP-2 is a transmembrane glycoprotein with both extracellular and intracellular components that is involved in calcium signal transduction [15]. It was first discovered by Lipinski et al. who raised antibodies against the human choriocarcinoma cell line [16]. These initial experiments demonstrated TROP-2 expression in normal trophoblasts and allowed for trophoblast cell growth, migration, and proliferation [17]. TROP-2 has been implicated in several cell signaling pathways including intracellular calcium transduction, MAPK signaling pathway, RAF, NF-kB and Cyclin D/E among others [15,18].

While initial investigation focused on TROP-2 expression in normal tissue, subsequent analysis showed that TROP-2 is upregulated in cancer cells when compared to normal cell counterparts [19]. This increased expression has been seen in many different tumor types including breast cancer, colon cancer, non-small cell lung cancer (NSCLC), esophageal squamous cell cancer, thyroid cancer and hepatobiliary cancers, raising the possibility of TROP-2 as a tumor agnostic biomarker [17,18,20]. The reason for TROP-2 overexpression in cancer cells is unclear, however it is postulated that TROP-2 has critical regulatory effects on cell proliferation and invasion, meaning that overexpression would lead to selective tumor progression [21]. In fact, preclinical data suggests that TROP-2 overexpression stimulates tumor growth while TROP-2 knock-down inhibits tumor growth [19].

In breast cancer specifically, elevated TROP-2 expression has been associated with worse survival [22]. TROP-2 gene expression has been detected in all breast cancer subtypes with higher levels noted in HR-/HER2- and triple negative breast cancer (TNBC) compared to HER2+ disease [23]. Genomic analyses of TNBC also identified TROP-2 as a novel biomarker [17]. The reason for TROP-2 overexpression is unclear, however it is postulated that TROP-2 has critical regulatory effects on cell proliferation and invasion, meaning that overexpression would lead to selective tumor progression [21]. In fact, preclinical data suggests that TROP-2 overexpression stimulates tumor growth while TROP-2 knock-down inhibits tumor growth [19].

In breast cancer specifically, elevated TROP-2 expression has been associated with worse survival [22]. TROP-2 gene expression has been detected in all breast cancer subtypes with higher levels noted in HR-/HER2- and triple negative breast cancer (TNBC) compared to HER2+ disease [23]. Genomic analyses of TNBC also identified TROP-2 as an attractive candidate for targeted therapy [24] and led to further investigation of TROP-2 as a new therapeutic target.

1.4. Sacituzumab govitecan: TROP-2 ADC

Initial preclinical therapeutic development focused on the combination of anti-TROP-2 antibodies with several chemotherapeutic partners including doxorubicin and microtubule inhibitors [25,26]. Among the most promising of these was sacituzumab govitecan (SG), a novel ADC that combines the humanized RST (hRST) anti-TROP-2 MAb to SN-38, an active metabolite of irinotecan, using a hydrolysable linker (Fig. 1). The anti-TROP-2 MAb allows SG to bind to the surface of cells expressing TROP-2 and is transported to intracellular lysosomes [27]
and hydrolyzed releasing SN-38 into the cell. SN-38 inhibits activity of topoisomerase I, thereby disrupting cellular apoptosis and resulting in DNA damage [18,28].

There are several reasons why SG is uniquely suited as an ADC. Firstly, its active metabolite SN-38 is estimated to be 2–3 times more potent than irinotecan and is also membrane permeable, enabling it to exert a "bystander effect" [28,29]. Second, the hydrolysable linker of SG allows for extracellular release of SN-38 in addition to intracellular release, thereby creating another mechanism for "bystander effect". This potential for extracellular release may be particularly beneficial in tumors with heterogenous TROP-2 expression [18,28,29]. Third, SG offers a high DAR of 7.6.1. Prior ADCs, such as T-DM1, had DARs of 4:1 or less, however the unique antibody and linker design allows for SG to maintain a higher DAR without compromising antibody binding or pharmacokinetic properties [27,30]. Finally, SG showed reduced toxicity compared to other topoisomerase inhibitors, particularly with less severe diarrhea. This is postulated to be due to the lower rate of glucuronidation of SN-38 molecules bound to antibody, as opposed to SN-38 that is metabolized directly from irinotecan [31].

1.5. Sacituzumab govitecan in TNBC

Initial clinical trials focused on the use of SG in metastatic TNBC (Table 1). A first in-human phase I/II basket trial (NCT01631552) enrolled 25 patients with solid tumors, including 4 patients with TNBC [32]. Patients were enrolled at doses ranging from 8 to 18 mg/kg on Day 1 and 8 of a 21-day cycle. They were not pre-selected based on TROP-2 expression. Dose-limiting neutropenia was observed at the 12 mg/kg dose and thus a dose of 10 mg/kg was selected for further study. Of the four TNBC patients, three had partial response (PR) with duration of response (DoR) of 10.4, 6.9, and 3.1 months respectively.

This led to IMMU-132-01 (NCT01631552), a phase I/II multi-center basket trial which enrolled 108 patients with TNBC and a least 2 prior lines of chemo to receive 10 mg/kg of SG on Day 1 and 8 of a 21-day cycle [33]. Overall response rate (ORR) was 33.3% (36 patients) including 3 complete responses (CR), median DoR was 7.7 months (95% confidence interval [CI], 4.9 to 10.8), and clinical benefit rate (CRR) was 45.4%. Efficacy was not affected by prior exposure to taxanes and anthracyclines, suggesting a lack of cross-resistance to previous cytotoxic therapy. The most common AE was diarrhea (62%) with the majority being low grade and only 8% having grade 3 or higher. Other common AEs of any grade included fatigue, nausea, neutropenia and anemia. The most common grade 3 or greater AEs were neutropenia (26%) and anemia (11%). The rate of AEs leading to treatment discontinuation was low (3%). Overall, these results supported ongoing evaluation of SG in refractory metastatic TNBC as a potentially efficacious treatment with a favorable safety profile.

Building on IMMU-132-01, the ASCENT trial (NCT02574455) randomized 468 patients with TNBC with at least 2 prior lines and a taxane in a 1:1 fashion to receive SG vs single-agent chemotherapy with eribulin, vinorelbine, capcitabine, or gemcitabine [34]. Patients with stable brain metastases were allowed to participate in the trial but were excluded from final analyses. A median PFS of 5.6 months with SG and

Table 1

| NCT Number/ Trial name (if applicable) | Trial Design/Patient Population | Clinical Trial Data | Reference |
|---------------------------------------|---------------------------------|---------------------|-----------|
| NCT01631552                           | FII trial evaluating multiple doses of IMMU-132 (Sacituzumab govitecan) in patients with advanced solid tumors including TNBC (N = 69) | DLT: neutropenia; MTD: 12 mg/kg Neutropenia was the most common G3 AE (n = 9) Two PRs per RECIST v1.1 (TNBC, colon cancer) SD: 64%; ORR: 33.3%; CBR: 45.4%; Median PFS: 5.5 months; and median OS: 16.6 months | 32 |
| NCT02574455 ASCENT                     | Phase II trial of Sacituzumab govitecan vs TPC in relapsed/refractory metastatic TNBC (N = 468) | Statistically significant improvement in median PFS and OS with SG compared to TPC. Myelosuppression and diarrhea were more frequent with SG | 34 |
| NCT04230109 neoSTAR                    | Phase II neoadjuvant trial with Sacituzumab govitecan administered q21 days × 4 cycles in patients with T1c-T4, node+. TNBC (N = 50) | pCR (ypT0/isN0) was 30%; Most common AEs were nausea, fatigue and alopecia. G3/AE neutropenia and G3 diarrhea were also observed. | 35 |
| NCT01631552                           | Ph I/II single arm basket trial of Sacituzumab govitecan including HR+/HER2- MBC treated with prior ET and chemotherapy (N = 54) | ORR: 31.5%, median DoR: 8.7 months; median PFS and OS: 5.5 months and 12 months respectively. G3 neutropenia: 50% | 43 |
| NCT03901339 TROPICS-02                 | Phase III trial of Sacituzumab govitecan vs TPC in HR+/HER2- MBC (N = 468) | Statistically significant improvement in median PFS and OS with SG compared to TPC. G3 neutropenia 51% on SG vs 38% on TPC, and G3 diarrhea 9% with SG vs 1% with TPC. Febrile neutropenia comparable on both arms. Unplanned subgroup analysis showed superior median PFS in patients with HER2-low | 45, 46, 49 |

(continued on next page)
Table 1 (continued)

| NCT Number/ Trial name (if applicable) | Clinical Trial Data | Reference |
|----------------------------------------|---------------------|-----------|
| Datopotamab deruxtecan NCT03401385 TROPION PanTumor01 | ORR 34% (ORR-52% in patients without prior topoisomerase I inhibitor-based ADC) G3 stomatin in 9.1% and G3 naunes in 6.8% of patients | 55 |
| Phase Ib/II platform trial with Datopotamab deruxtecan + durvalumab in first-line metastatic TNBC (N = 44) BEGONIA | Confirmed ORR: 74%; median DoR not yet reached. Responses seen regardless of PD-L1 expression. No DLTs reported; G3 stomatisin in 14%. No ILD/pneumonitis or neutropenic events reported | 62 |

Abbreviations: ADC = antibody drug conjugate; AE = adverse events; CBR= Clinical benefit rate; DLT = dose limiting toxicities; DoR = Duration of response; FIH = First-in-human; G = grade; HR = hazard ratio; HD = hormone receptor positive; IHC = Immunohistochemistry; ILD = Interstitial lung disease; MBC = metastatic breast cancer; MTD = maximum tolerated dose; NACT = neoadjuvant chemotherapy; OS = overall survival; PFS = progression free survival; PR = partial response; pCR = pathologic complete response; TNCB = triple negative breast cancer; TPC = treatment of physician’s choice chemotherapy.

1.7 months with chemotherapy (HR 0.41; 95% CI, 0.32 to 0.52; P < 0.001) and median OS of 12.1 months with SG vs 6.7 months with chemotherapy (HR 0.48; 95% CI, 0.38 to 0.59; P < 0.001), and DoR of 6.3 months with SG vs 3.6 months with chemotherapy (HR 0.39; 95% CI, 0.14 to 1.07) were reported. Efficacy analysis of the full population, including those patients with brain metastases, found a median PFS of 4.8 months with SG and 1.7 months with chemotherapy (HR 0.43; 95% CI, 0.35 to 0.54). Overall, the results of ASCENT demonstrated a statistically significant survival benefit with the use of SG over single-agent chemotherapy for patients with metastatic TNBC in the second line setting and beyond. The incidence of AEs, particularly neutropenia and diarrhea, was consistent with prior early phase studies of SG and were more common in the SG group compared to chemotherapy. However, despite the higher rate of toxicity with SG, only 5% of patients treated with SG had to discontinue treatment due to adverse AE, indicating that these AEs can be effectively medically managed.

NeoSTAR (NCT04230109) evaluated SG for TNBC in the neoadjuvant setting for localized disease [35]. After four cycles of SG, patients with biopsy proven residual disease had the option of continuing with further neoadjuvant therapy. Fifty patients were enrolled in the study with the majority (62%) being node-negative. Most patients had radiologic response after 4 cycles (62%) and 26 (52%) proceeded straight to surgery with a pCR rate of 30% (Table 1). The remaining 24 patients received additional neoadjuvant chemotherapy (antracycline-based regimen vs carboplatin/taxane vs docetaxel/cyclophosphamide) with 6 of them achieving pCR. While this was an early phase trial with a small population size, these results suggest that ADCs could be used to select patients with good prognostic features that may be able to be spared further chemotherapy.

There are several ongoing trials for SG in TNBC. Among the early phase trials is Saci-IO (NCT04468061) a phase II trial randomizing patients with chemotherapy naïve metastatic TNBC to SG with or without pembrolizumab [36]. Morphus TNBC (NCT03424005) is a phase Ib/II study that will enroll multiple parallel arms for patients with metastatic TNBC in the first- or second-line setting for those who are immunotherapy naïve [37]. Other trials evaluating the combination of SG with immunotherapy include InCITe (NCT03971409), a phase II trial evaluating SG with avelumab vs avelumab with liposomal doxorubicin with or without binimetinib for metastatic TNBC and, and a phase I/II trial combining SG with cyclophosphamide and two novel agents, N-803, and PD-L1 t-haNK (NCT04927884) [38,39]. N-803 is a protein complex which functions as a super-agonist of IL15 and PD-L1 t-haNK is an engineered natural killer cell which expresses IL2, CD16 and a high affinity receptor for PD-L1. Finally, a phase I/II trial is combining SG with talazoparib in patients with metastatic TNBC (NCT04039230) [40]. There are two ongoing phase III trials of note: i) ASCENT-03 evaluating SG versus physician’s choice of chemotherapy in patients with metastatic TNBC with PD-L1 negative tumors or PD-L1 positive and have already undergone treatment with immune checkpoint inhibitor (CPI) [41] and ii) ASCENT-04 evaluating pembrolizumab combined with either SG or physician’s choice of chemotherapy in patients with metastatic TNBC and PD-L1 positive (combined positive score ≥10) tumors [42] (Table 2).

1.6. Sacinuzumab govitacan in HR+ breast cancer

The success of SG in TNBC prompted its evaluation in other breast cancer subtypes, particularly HR+. IMMU-132-01 was a phase I/II single-arm basket trial (NCT01635152) that enrolled 54 patients with metastatic HR+/HER2-breast cancer that had progressed on endocrine therapy (ET) and at least one line of chemotherapy [43]. At a median follow-up of 11.5 months, ORR was 31.5% with 17 partial responses. Median DoR was 8.7 months, median PFS was 5.5 months (95% CI 3.6–7.6), and median OS was 12 months (95% CI 9.0–18.2) (Table 1). This led to the phase III trial TROPICS-02 (NCT03901339) which evaluated SG in metastatic HR+/HER2-breast disease [44] vs. TPC chemotherapy (erbulin, gemcitabine, cabazitaxel or vinorelbine). Eligible patients had HR+/HER2- MBC with 2–4 prior lines of chemotherapy for metastatic disease, and prior therapy including a taxane, CDK4/6 inhibitor and ET. Five hundred and forty-three patients were randomized 1:1 to receive SG or chemotherapy. At the first interim analysis (IA), SG was associated with a statistically significant improvement in PFS compared to TPC (5.5 vs 4.0 months, HR 0.66; 95% CI, 0.53–0.83; P = 0.0003) [45]. In a planned second IA with a median follow-up of 12.5 months, treatment with SG was associated with statistically significant improvement in OS (14.4 vs 11.2 months; HR 0.79; 95% CI, 0.65–0.96 P = 0.020) compared with TPC [46]. In addition to PFS and OS, ORR (21% vs 14%, HR 1.63; 95% CI 1.03–2.56, P = 0.035) and CBR (34% vs 22%; HR 1.80; 95% CI 1.23–2.63, P = 0.003) were significantly higher in patients receiving SG versus chemotherapy (Table 1). More patients in the SG group had grade 3 or greater AEs with 74% vs 60% in the chemotherapy group. The most common of these were neutropenia (51% vs 39%) and diarrhea (10% vs 1%). Interestingly, an analysis of patient reported outcomes revealed an association between improved quality of life with use of SG compared to chemotherapy as determined by responses to European Organization for Research and Treatment (EORTC) quality of life questionnaire-C30 [47]. Median time to deterioration in global health quality of life was longer with SG compared to chemotherapy (4.3 vs 3 months, HR 0.75; 95% CI 0.61–0.92, p = 0.006). Due to interest in efficacy in patients with low HER2 expression (HER2 IHC 0 tumors (local testing) with SG compared to TPC.

Further studies to establish the role of SG in HR+/HER2-breast cancer (BC) are needed and are ongoing. SASCIA is a phase III trial for...
patients with localized HER2-BC (including TNBC and HR+) with residual disease after neoadjuvant chemotherapy [50]. Patients are randomized to receive 8 cycles of SG or physician’s choice of therapy (capecitabine vs platinum-based chemotherapy vs observation) (Table 2). Saci-IO HR+ (NCT04448886) is a phase II trial evaluating the use of SG with or without pembrolizumab in patients with metastatic HR+/HER2-BC following progression on ET [51]. Finally, a phase II study (NCT04647916) is evaluating the efficacy of SG in patients with metastatic HER2-BC and brain metastases [52]. The primary outcome of this study is CNS response.

2. Datopotamab deruxtecan (Dato-DXd)

Dato-DXd is a TROP-2-directed ADC where a humanized anti-TROP-2 IgG1 MAb is attached to a topoisomerase I inhibitor payload via tetrapeptide-based cleavable linker. The DAR in this construct is ~4:1 [53]. It is highly stable in circulation due to the linker which is designed for cleavage only in the presence of lysosomal proteases. Although the payload (DXd) shares the same mechanism of action (MOA) as the payload (SN-38) in SG, there are some important differences between them. DxD is 10X more potent than SN-38. The longer half-life of Dato-DXd allows a Q3 week dosing schedule which is preferable over the 90% of payload released after 3 days with sacituzumab [54].

In preclinical studies, Dato-DXd inhibited growth in cell lines of tumors that expressed only in the presence of lysosomal proteases. Although the payload (DXd) shares the same mechanism of action (MOA) as the payload (SN-38) in SG, there are some important differences between them. DxD is 10X more potent than SN-38. The longer half-life of Dato-DXd allows a Q3 week dosing schedule which is preferable over the 90% of payload released after 3 days with sacituzumab [54].

In preclinical studies, Dato-DXd inhibited growth in cell lines of multiple tumor types that expressed high levels of TROP-2, but not those with low TROP-2 [53]. All these cell lines were sensitive to DxD alone while datopotamab or an isotype control IgG ADC alone were not active thus confirming that expression of TROP-2 on the cell surface is essential for Dato-DXd activity. Studies in xenograft mouse models demonstrated that treatment of TROP-2-expressing tumors with Dato-DXd led to accumulation of DXd and DNA damage in tumor cells resulting in inhibition of tumor growth [53].

2.1. Clinical trials with Dato-DXd

The first-in-human (FIH) trial with Dato-DXd enrolled unselected patients with advanced solid tumors including TNBC and HR+/HER2-MBC. Forty-four patients with metastatic TNBC and a median of 3 prior regimens for advanced disease were treated with Dato-DXd [55]. Nearly a third had de novo MBC and over two-thirds had received 2 or more priors for MBC. Eleven percent of patients had brain metastases. Thirty percent of patients (n = 13) had received prior topoisomerase-I inhibitor-based ADC, SG (n = 10), and a DXd-based ADC (n = 3). An ORR of 34% was observed with confirmed responses in 32% of patients (ORR 52% and confirmed responses in 48% in SG/DXd naïve patients). Median DoR was not reached (Table 1). Grade 3 or greater AEs were seen in 45%, and the most common AEs were nausea (66%) and stomatitis (55%); majority of these were grade 1–2, but 9% grade 3 stomatitis was reported. The frequency of diarrhea and hematologic toxicity was low. There were no adjudicated cases of drug-related interstitial lung disease (ILD). Based on these encouraging data, a phase III trial evaluating Dato-DXd vs investigator choice of chemotherapy as first-line therapy for metastatic TNBC was initiated [56].

The FIH trial also enrolled patients with refractory HR+/HER2-MBC and although these data have not been publicly shared, a randomized phase III trial of Dato-DXd vs TPC in HR+/HER2-MBC previously treated with 1–2 lines of chemotherapy is underway [57] (Table 2).

Chemotherapy, including topoisomerase I inhibitors, can enhance the efficacy of CPIs providing an opportunity to combine immune CPI therapy with Dato-DXd [58]. In syngeneic mouse models, DxD bearing ADCs sensitized tumors to CPI, potentially through enhanced antitumor immunity caused by the delivered DXd payload [59, 60]. This was demonstrated with T-DXd and there are ongoing preclinical studies with Dato-DXd [59]. BEGONIA is a phase Ib/II trial testing this concept in the clinical setting with the durvalumab + Dato DXd combination in first-line metastatic TNBC [61]. In the 27 patients evaluable for response, the confirmed ORR was 74% (18/24 PR), regardless of PD-L1 expression (evaluated by the SP263 assay) [62]. Most patients had durable responses and median DoR was not reached. Stomatitis and alopecia were the most frequent toxicities, mostly low-grade events, although grade 3 stomatitis was reported in 4 patients (14%) and ~14% of patients required dose reductions due to stomatitis. There were no cases of ILD/pneumonitis and no neutropenic events were reported [62]. The low rates of hematologic toxicities observed with Dato-DXd may enable combinations with PARP inhibitors. This doublet therapy is attractive since both agents target DNA damage and repair pathway [63]. TROPION Pantumor-03 is being planned (NCT05489221) in patients with advanced solid tumors (although not breast cancer) with
Dato-DXd plus AZD5305 (a potent inhibitor of PARP1 with significant PARP1 DNA trapping activity at doses that showed no PARP2 activity) included as one of the treatment arms.

2.2. Adverse events with TROP-2 ADCs

ADCs generally incorporate highly potent and toxic drugs to achieve maximum cytotoxic effects on the target tumor cells. Hence, the side effect profile of these ADCs may be characteristic of the cytotoxic payload. Some of the most common AEs reported on the sacituzumab arm in the pivotal ASCENT trial were neutropenia (63%), diarrhea (59%) and nausea (57%) [34]. Neutropenia was also the most frequent grade 3/4 AE (51%) and the incidence of grade 3 and 4 febrile neutropenia was 5% and 1% respectively. The incidence of grade 3 diarrhea was 10% with SG; no grade 4 events were noted. Both neutropenia and diarrhea are known side effects of SN-38 that is derived from irinotecan. These clinically relevant AEs were managed by utilizing standard supportive care measures. The reported incidence of ILD was very low with one patient having grade 3 pneumonitis following the last dose of SG therapy. It was resolved in 7 weeks without any sequelae [64]. Phase III TROPION-02 study in HR+/-HER2- MBC also reported similar rates of neutropenia (all grade 70%; Grade 3 5%), diarrhea (all grade 57%; Grade 3–9%) [46].

A detailed biomarker analysis from the ASCENT trial demonstrated that the toxicity profile of sacituzumab was not influenced by the level of TROP-2 expression in the tumor [65]. In a retrospective exploratory analysis in the phase I/II basket trial with SG, the incidence of neutropenia, but not diarrhea, was shown to increase with increasing UGT1A1*28 copy number [33]. A detailed exploratory safety analysis from the ASCENT trial also revealed that patients with UGT1A1*28/*28 genotype (13% of patients on the SG arm) had significantly higher rates of neutropenia (59%) compared to the heterozygous (47%) and wild type (53%) variants but considerably higher rates of febrile neutropenia (18% vs 5% vs 3% respectively) [64]. However, rates of grade ≥3 treatment-related diarrhea, although more common in UGT1A1*28/*28 genotype, were not that different between the genotypes (15% vs 9% vs 10% respectively). The authors noted that rates of treatment discontinuation for SG due to toxicities was low in patients with the UGT1A1*28/*28 genotype (6%). One caveat from these exploratory analyses was the low frequency of the UGT1A1*28/*28 genotype that precluded any firm conclusions in the differences in AEs. While mandatory prescreening for UGT1A1 genotype is not required and UGT1A1 status does not warrant upfront changes in treatment or management, individuals with UGT1A1*28/*28 genotype should be closely monitored for neutropenia and diarrhea and dose reduced in the event of toxicity [64].

Dato-DXd treatment in heavily pretreated TNBC resulted in a low frequency of hematologic toxicities and diarrhea in the TROPION Pan-Tumor01 trial [55]. The stable linker and the long half-life of Dato-DXd may result in less payload release into the plasma limiting myelosuppression [53]. The most common AEs reported in this trial were mainly low-grade nausea (~60%) and stomatitis (~45%), although grade 3 stomatitis was reported in ~10–12% of patients [55]. There were no cases of adjudicated drug-related ILD noted on this trial. A similar toxicity profile was observed in the BEGONIA trial in the Dato-DXd + durvalumab arm with all grade stomatitis in 69% of patients and all grade nausea and alopecia in 66% of patients. Grade 3 stomatitis was reported in 14% of patients and 21% had grade 2 nausea and alopecia [62]. Stomatitis led to dose reductions in 14% of patients necessitating prophylactic measures and implementation of toxicity management guidelines. No neutropenic events or cases of ILD/pneumonitis were reported.

2.3. Predictive biomarkers of TROP-2 directed ADCs

Currently there are no predictive biomarkers for treatment decisions regarding SG or Dato-DXd. In the ASCENT study, an exploratory biomarker analysis for patients undergoing SG treatment was performed using BRCAl/2 status as well as an H-score. The H-score is a score that utilizes an IHC stain for TROP-2 on tumor tissue and evaluates the intensity and percentage of cells that stain positive [34,67]. Two hundred and ninety patients in the study (60%) had evaluable specimens and patients were divided into those having high, medium and low H-scores. In patients treated with SG, those with high H-score had numerically higher OS compared to those with low score (14.2 vs 9.3 months) but this difference was not statistically significant. However, the small number of patients with low TROP-2 expression limited the analyses. Similarly, no difference in efficacy was noted for those with or without a BRCA mutation. An earlier phase I/II trial noted numerically higher PFS in those with moderate to high TROP-2 expression but again, this result was not statistically significant [66]. More investigation is needed to identify biomarkers predictive of benefit to TROP-2 ADCs.

3. Conclusion

ADCs have greatly expanded treatment options for patients with breast cancer (BC). They are able to deliver a potent cytotoxic that could not be given alone to the tumor through selective antibodies. Early efforts at implementing ADCs in MBC focused on HER2-directed agents and subsequent ADCs have expanded to target TROP-2 across multiple breast cancer subtypes. Sacituzumab govetecan, a TROP-2 ADC was initially approved for metastatic TNBC regardless of TROP-2 expression and most recently reported significant improvements in PFS and OS in hormonally driven BC as well. Data from trials with Dato-DXd in TNBC and HR+ disease are likely to further impact treatment in this space in the near future as well.

Given the astounding poor performance of single agent chemotherapy in both TNBC and endocrine-resistant ER + MBC and the significant improvements with multiple ADCs compared to standard of care chemotherapy, it is anticipated that ADCs will continue to outperform chemotherapy in even earlier lines of breast cancer. Most ADCs also boast an attractive side effect profile compared to standard chemotherapy, and so far, are reasonable treatment choices across a wide spectrum of target protein expression.

Combinations are of interest with ADCs, however, it remains to be determined whether a) they add additional efficacy to a class of compounds that are already quite active, and b) if combinations add toxicity, making them undesirable. Ongoing trials are replacing conventional chemotherapeutic agents with SG as a partner for immunotherapy in the front-line setting for metastatic TNBC (ASCENT-04, Saci-IO TNBC, Morpheus TNBC) and in recurrent TNBC (InCITe) as well as refractory HR+/-HER2- MBC (Saci-IO HR+). This strategy avoids use of drugs that patients may have been exposed to in the (neo)adjuvant setting. Moreover, SG does not cause the permanent toxicities like neurotoxicity and cardiac issues associated with taxanes and anthracyclines used to treat TNBC. Other combinations that can be envisaged include targeted therapies and a trial of SG + alpelisib in PIK3CA mutant HER2- MBC is already underway (NCT05143229) but may magnify GI toxicity [69].

In early stage disease TNBC, the modest pCR rates with 12 weeks of SG as neoadjuvant treatment suggest that the optimal duration of therapy needs to be evaluated and combination therapies must be explored to improve outcomes. Single agent SG is under evaluation in patients with residual disease after neoadjuvant chemotherapy for HER2- BC (SASCIA) and early safety analyses noted that patients treated with SG reported higher frequency and higher-grade AEs compared to those treated with capecitabine on the control arm [70]. This does underscore the need to adhere to guidelines for supportive care therapies, especially in the curative setting.

The success of targeting TROP-2 via ADCs in MBC and urothelial cancer and ongoing trials in NSCLC have established TROP-2 targeting as a valid and fruitful strategy. Future research needs to focus on optimizing the side effect profile and identification of predictive biomarkers...
to tailor treatment.

Novel ADC agents are anticipated and are currently being explored in clinical trials. These include patritum deruxtecan, a HER3-targeting ADC with the same payload as T-DXd and enfuramab vedotin with an antibody targeting Nectin-4 and MMAE as the payload. One very important consideration will be sequencing and mechanisms of resistance. It is unclear whether resistance will occur from loss of target expression from the cell surface, resistance to the payload, or alternative mechanisms. This could greatly impact our ability to use ADC after ADC and how we prioritize and sequence emerging ADC agents.

Funding

This publication was not funded by any public, commercial or not-for-profit organization.

Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Erika Hamilton’s institution has received research funding from multiple entities (see below).

| Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|
| Abbvie | Research Funding - Paid to Institution |
| Acerta Pharma | Research Funding - Paid to Institution |
| Accutol Biotechnology | Research Funding - Paid to Institution |
| ADC Therapeutics | Research Funding - Paid to Institution |
| AKE55990 Australia | Research Funding - Paid to Institution |
| Amgen | Research Funding - Paid to Institution |
| Aravive | Research Funding - Paid to Institution |
| ArQule | Research Funding - Paid to Institution |
| Artios | Research Funding - Paid to Institution |
| Arvinas | Research Funding - Paid to Institution |
| AtlasMedX | Research Funding - Paid to Institution |
| Black Diamond | Research Funding - Paid to Institution |
| Bliss BioPharmaceuticals | Research Funding - Paid to Institution |
| Boehringer Ingelheim | Research Funding - Paid to Institution |
| Canaccord Therapeutics | Research Funding - Paid to Institution |
| Clovis | Research Funding - Paid to Institution |
| Compugen | Research Funding - Paid to Institution |
| Cullen-Florentine | Research Funding - Paid to Institution |
| Curis | Research Funding - Paid to Institution |
| CytoPharma | Research Funding - Paid to Institution |
| Dana Farber Cancer Inst | Research Funding - Paid to Institution |
| Dantari | Research Funding - Paid to Institution |
| Deciphera | Research Funding - Paid to Institution |
| Duality Biologics | Research Funding - Paid to Institution |
| EFFECDR Therapeutics | Research Funding - Paid to Institution |
| Ellipses Pharma | Research Funding - Paid to Institution |
| Elucida Oncology | Research Funding - Paid to Institution |
| EMD Serono | Research Funding - Paid to Institution |
| Fochon | Research Funding - Paid to Institution |
| Fujifilm | Research Funding - Paid to Institution |
| GI Therapeutics | Research Funding - Paid to Institution |
| H3 Biomedicine | Research Funding - Paid to Institution |
| Harpoon | Research Funding - Paid to Institution |
| Hutchinson MedPharma | Research Funding - Paid to Institution |
| Immunogenics | Research Funding - Paid to Institution |
| ImmunoMedics | Research Funding - Paid to Institution |
| Incyte | Research Funding - Paid to Institution |
| Infinity Pharmaceuticals | Research Funding - Paid to Institution |
| Inventivbio | Research Funding - Paid to Institution |
| Jacobus | Research Funding - Paid to Institution |
| Karyopharm | Research Funding - Paid to Institution |
| Leap Therapeutics | Research Funding - Paid to Institution |
| Lilly | Research Funding - Paid to Institution |
| Lycera | Research Funding - Paid to Institution |
| Mallinckrodt Biologies | Research Funding - Paid to Institution |
| Macrogenics | Research Funding - Paid to Institution |
| MedImmune | Research Funding - Paid to Institution |

Erika Hamilton’s institution has received consulting fees from multiple entities (see below).

| Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|
| Abbvie | Consulting - Paid to Institution |
| Acerta Pharma | Consulting - Paid to Institution |
| Accutol Biotechnology | Consulting - Paid to Institution |
| ADC Therapeutics | Consulting - Paid to Institution |
| AKE55990 Australia | Consulting - Paid to Institution |
| Amgen | Consulting - Paid to Institution |
| Aravive | Consulting - Paid to Institution |
| ArQule | Consulting - Paid to Institution |
| Artios | Consulting - Paid to Institution |
| Arvinas | Consulting - Paid to Institution |
| AtlasMedX | Consulting - Paid to Institution |
| Black Diamond | Consulting - Paid to Institution |
| Bliss BioPharmaceuticals | Consulting - Paid to Institution |
| Boehringer Ingelheim | Consulting - Paid to Institution |
| Canaccord Therapeutics | Consulting - Paid to Institution |
| Clovis | Consulting - Paid to Institution |
| Compugen | Consulting - Paid to Institution |
| Cullen-Florentine | Consulting - Paid to Institution |
| Curis | Consulting - Paid to Institution |
| CytoPharma | Consulting - Paid to Institution |
| Dana Farber Cancer Inst | Consulting - Paid to Institution |
| Dantari | Consulting - Paid to Institution |
| Deciphera | Consulting - Paid to Institution |
| Duality Biologics | Consulting - Paid to Institution |
| EFFECDR Therapeutics | Consulting - Paid to Institution |
| Ellipses Pharma | Consulting - Paid to Institution |
| Elucida Oncology | Consulting - Paid to Institution |
| EMD Serono | Consulting - Paid to Institution |
| Fochon | Consulting - Paid to Institution |
| Fujifilm | Consulting - Paid to Institution |
| GI Therapeutics | Consulting - Paid to Institution |
| H3 Biomedicine | Consulting - Paid to Institution |
| Harpoon | Consulting - Paid to Institution |
| Hutchinson MedPharma | Consulting - Paid to Institution |
| Immunogenics | Consulting - Paid to Institution |
| ImmunoMedics | Consulting - Paid to Institution |
| Incyte | Consulting - Paid to Institution |
| Infinity Pharmaceuticals | Consulting - Paid to Institution |
| Inventivbio | Consulting - Paid to Institution |
| Jacobus | Consulting - Paid to Institution |
| Karyopharm | Consulting - Paid to Institution |
| Leap Therapeutics | Consulting - Paid to Institution |
| Lilly | Consulting - Paid to Institution |
| Lycera | Consulting - Paid to Institution |
| Mallinckrodt Biologies | Consulting - Paid to Institution |
| Macrogenics | Consulting - Paid to Institution |
| MedImmune | Consulting - Paid to Institution |

Hope S Rugo reports the following:

Merck Research Funding - Paid to Institution
Mersana Research Funding - Paid to Institution
Merus Research Funding - Paid to Institution
Millennium Research Funding - Paid to Institution
Molecular Templates Research Funding - Paid to Institution
Myriad Genetic Laboratories Research Funding - Paid to Institution
Novartis Research Funding - Paid to Institution
Nucana Research Funding - Paid to Institution
Olema Research Funding - Paid to Institution
OncoMed Research Funding - Paid to Institution
Onconova Therapeutics Research Funding - Paid to Institution
ORIC Pharmaceuticals Research Funding - Paid to Institution
Orinove Research Funding - Paid to Institution
Pfizer Research Funding - Paid to Institution
PharmaMar Research Funding - Paid to Institution
Pieris Pharmaceuticals Research Funding - Paid to Institution
Pionyr Immunotherapeutics Research Funding - Paid to Institution
Flexxion Research Funding - Paid to Institution
Radius Health Research Funding - Paid to Institution
Regeneron Research Funding - Paid to Institution
Relay Therapeutics Research Funding - Paid to Institution
Repertoire Immune Medicine Research Funding - Paid to Institution
Rgenix Research Funding - Paid to Institution
Roche/Genentech Research Funding - Paid to Institution
SeaGen Research Funding - Paid to Institution
Seronox Pharmaceuticals Research Funding - Paid to Institution
Shattuck Labs Research Funding - Paid to Institution
Silverback Research Funding - Paid to Institution
Sutro Research Funding - Paid to Institution
Syndax Research Funding - Paid to Institution
Syros Research Funding - Paid to Institution
Taiho Research Funding - Paid to Institution
TapImmune Research Funding - Paid to Institution
Tesaro Research Funding - Paid to Institution
Tolmar Research Funding - Paid to Institution
Torque Therapeutics Research Funding - Paid to Institution
Treatwell Therapeutics Research Funding - Paid to Institution
Verastem Research Funding - Paid to Institution
Vincera Pharma Research Funding - Paid to Institution
Zenith Epigenetics Research Funding - Paid to Institution
Zymeworks Research Funding - Paid to Institution

(continued on next column)
References

[1] Srebrzicki K, Ulrich A. Paul Ehrlich’s magic bullet concept: 100 years of progress. Nat Rev Cancer 2008 Jun;8(6):473–80. https://doi.org/10.1038/nrc2394, Epub 2008 May 12.

[2] Junmita TT, Li G, Parsons K, Phillips GJ, Slawickowski MX. Trastuzumab-DMI (T-DMI) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res Treat 2011 Jul;128(2):347–56. https://doi.org/10.1007/s10549-010-1090-x, Epub 2010 Aug 21.

[3] Mach JP, Carrell S, Forini M, Ritchard J, Donah A, Albert P. Tumor localization of radiolabeled trastuzumab against carcinobromic antigen in patients with carcinoma: a critical evaluation. N Engl J Med 1980 Jul 3;303(13):15–10. https://doi.org/10.1056/NEJM19800703303030102.

[4] Feicher BA, Chari RJV. Antibody conjugate therapeutics: challenges and potential. Clin Cancer Res 2011 Oct 15;17(20):6389–97. https://doi.org/10.1158/1078-0432.CCR-11-1417.

[5] Mahalingaiah PK, Curlinnios R, Durbin KR, Yeager RL, Philip BK, Bawa B, et al. Potential mechanism of target-independent uptake and toxicity of antibody-drug conjugates. Pharmacoel Therap 2019 Aug 11;210:105. https://doi.org/10.1038/s471-019-00048-w. Epub 2019 Apr 24.

[6] Jain N, Smith SW, Ghone S, Tomczuk B. Current ADC linker chemistry. Pharm Res (N Y) 2015 Nov;32(11):3526–40. https://doi.org/10.1007/s11130-015-1657-7. Epub 2015 Mar 11.

[7] Drake PM, Rabuka D. An emerging playbook for antibody-drug conjugates: lessons from the laboratory and clinic suggest a strategy for improving efficacy and safety. Curr Opin Biotech 2015 Oct;28:174–80. https://doi.org/10.1016/j.coob.2015.08.005. Epub 2015 Sep 2.

[8] Conner SD, Schmid SL. Regulated portals of entry into the cell. Nature 2003 Mar 6;422(6927):37–42. https://doi.org/10.1038/nrc2394. Epub 2003 30 Feb 21. https://doi.org/10.18632/oncotarget.4318. Erratum in: Oncotarget. 2020 Mar 10;11(10):942.

[9] Mathijssen RH, van Alphen RJ, Verweij J, Loos WJ, Noote K, Stoter G, Sparreboom A. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 2001 Aug;7(18):5187–91.

[10] Kawato Y, Aonuma M, Hirota Y, Kuga H, Sato K. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT- 11. Cancer Res 1991 Oct 15;51(10):4197–91.

[11] Rispen T, Davies AM, Ooijevar-de Heer P, Abanah S, Bende O, Sutton BJ, et al. Dynamics of inter-heavy chain interactions in human immunoglobulin G (IgG) subclasses studied by kinetic Fab arm exchange. J Biol Chem 2014 Feb 28;289(9):6079–90. https://doi.org/10.1074/jbc.M113.514183. Epub 2014 Jan 14. PMID: 24425871; PMCID: PMC3937676.

[12] Stein A, Voigt W, Jordan K. Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management. Ther Adv Med Oncol 2010 Jan;2(1):1–11. https://doi.org/10.1177/1758834009345164. PMID: 21789926; PMCID: PMC3126005.

[13] Starodub AN, Ocean JA, Shah MA, Guarino MJ, Picozzi Jr VJ, Vahdat LT, et al. First-in-Human trial of a novel anti-trop-2 antibody-SN-38 conjugate, sacituzumab govetecan, for the treatment of metastatic solid metastatic solid cancer. Clin Cancer Res 2015 Sep 1;21(17);3870–8. https://doi.org/10.1158/1078-0432.CCR-14-3321. Epub 2015 May 5. PMID: 25948002; PMCID: PMC4558321.

[14] Bardia A, Mayer LA, Vahdat LT, Tolomey SM, Ishakov SJ, Diamond JR, et al. Sacituzumab govetecan-haz in refractory metastatic triple-negative breast cancer. N Engl J Med 2019 Feb 21;380(8):741–51. https://doi.org/10.1056/NEJMoa1814213.

[15] Bardia A, Hurvitz SA, Tolomey SM, Loirat D, Punie K, Oliveira M, et al. ASCENT clinical trial investigators. Sacituzumab govetecan in metastatic triple-negative breast cancer. N Engl J Med 2021 Apr 22;384(16):1529–41. https://doi.org/10.1056/NEJMoa2049485.

[16] Spiliotis L, Tolomey SM, Dei NM, Fell G, Trippa L, Comander AH, et al. Phase 2 study of response-guided neoadjuvant sacituzumab govetecan (IMMU-132) in patients with localized triple-negative breast cancer: results from the NeoSTAR trial. J Clin Oncol June 1, 2022:10(16_suppl). https://doi.org/10.1200/JCO.22.0046.

[17] Garrido-Castro AC. Saci-IO TNBC: randomized phase II study of sacituzumab govetecan with or without pembrolizumab in PD-L1-negative metastatic triple negative breast cancer (TNBC). Clinical trial registration. clinicaltrials.gov; March 15, 2022. https://clinicaltrials.gov/ct2/show/NCT04685601.

[18] Hoffmann-La Roche. A phase Ib/II, open-label, multicenter, randomized umbrella study evaluating the efficacy and safety of multiple immunotherapy-based treatment combinations in patients with metastatic triple-negative breast cancer (Morpath-TNBC). Clinical trial registration. clinicaltrials.gov; August 1, 2022. https://clinicaltrials.gov/ct2/show/NCT03424005.

[19] Ruiz A, Arancibia E, Empl LA, Pena PJ, Faries J, Orendi A, et al. Potential treatment combinations in patients with metastatic triple-negative breast cancer (PNPC-TNBC). Clinical trial registration. clinicaltrials.gov; August 1, 2022. https://clinicaltrials.gov/ct2/show/NCT03424005.

[20] Ruiz A, Arancibia E, Empl LA, Pena PJ, Faries J, Orendi A, et al. Potential treatment combinations in patients with metastatic triple-negative breast cancer (PNPC-TNBC). Clinical trial registration. clinicaltrials.gov; August 1, 2022. https://clinicaltrials.gov/ct2/show/NCT03424005.

[21] Ruiz A, Arancibia E, Empl LA, Pena PJ, Faries J, Orendi A, et al. Potential treatment combinations in patients with metastatic triple-negative breast cancer (PNPC-TNBC). Clinical trial registration. clinicaltrials.gov; August 1, 2022. https://clinicaltrials.gov/ct2/show/NCT03424005.

[22] Ruiz A, Arancibia E, Empl LA, Pena PJ, Faries J, Orendi A, et al. Potential treatment combinations in patients with metastatic triple-negative breast cancer (PNPC-TNBC). Clinical trial registration. clinicaltrials.gov; August 1, 2022. https://clinicaltrials.gov/ct2/show/NCT03424005.
Kalinsky K, Diamond JR, Vahdat LT, Tolomey SM, Juric D, O'M. Shastry et al. Krop I, Juric D, Shimizu T, Tolcher A, Spira A, Mukohara T, et al. Datopotamab AstraZeneca. A phase 3, open-label, randomised study of datopotamab deruxtecan in advanced/metastatic HER2-negative breast cancer that have been treated with one or two prior lines of systemic chemotherapy (TROPiC-Breast01). Clinical trial registration. clinicaltrials.gov; July 22, 2022. https://clinicaltrials.gov/ct2/show/NCT05374512.

McKenzie JA, Mbofung RM, Malu S, Zhang M, Ashkin E, Devi S, et al. The effect of taxane-based chemotherapy on overall survival in patients with hormone receptor-positive breast cancer. J Natl Cancer Inst 2018 Jan 1;110(7):777–86. https://doi.org/10.1093/jnci/djy257.

Rugo HS, Bardia A, Tolaney SM, Arteaga C, Cortes J, Sohn J, et al. TROPiC-02: a Phase III study investigating sacituzumab govitecan in the treatment of HR-negative breast cancer, Future Oncol 2020 Apr;16(12):705–15. https://doi.org/10.2217/fon-2020-0163 . Epub 2020 Mar 30.

Rugo HS, Bardia A, Marmé F, Cortes J, Schmid P, Loirat D, et al. Sacituzumab govitecan in hormone receptor-negative/human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2020;38:3655–66. https://doi.org/10.1200/JCO.20.01002.

Rugo HS, Bardia A, Marmé F, Cortes J, Schmid P, Loirat D, et al. LBA76 - Overall survival (OS) results from the phase III TROPiC-02 study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in patients (pts) with HR-/-HER2- metastatic breast cancer (mBC), ESMO 2022. Ann Oncol 2022;33(suppl 7):S808–69. https://doi.org/10.1016/annonc/annonc1089.

Rugo HS, Schmid P, Tolaney SM, Dalene F, Marmé F, Shi L, et al. Health-related quality of life (HRQoL) in the phase 3 TROPiC-02 trial of sacituzumab govitecan (SG) vs chemotherapy in HR+/HER2- metastatic breast cancer (mBC), ESMO 2022.

Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med 2022 Jul 7;387(1):9–20. https://doi.org/10.1056/NEJMoa2203690. Epub 2022 Jun 5.

Schmid P, Cortes J, Marmé F, Rugo HS, Tolaney SM, et al. 214-MO - Sacituzumab govitecan (SG) efficacy in hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer (mBC) by HER2 immunohistochemistry (IHC) status in the phase III TROPiC-02 study, ESMO 2022. Ann Oncol 2022;33(suppl 7):S888–121. https://doi.org/10.1016/annonc/annonc1040.

German Breast Group. Phase III postneoadjuvant study evaluating sacituzumab govitecan, an antibody drug conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment - SASCIA. Clinical trial registration. clinicaltrials.gov; April 13, 2022. https://clinicaltrials.gov/ct2/show/NCT04595566.

Garrido-Castro, Ana C. Sacci-IO HR+:: randomized phase II study of sacituzumab govitecan with or without pembrolizumab in hormone receptor-positive (HR+)/HER2- metastatic breast cancer (MBC), Clinical trial registration. clinicaltrials.gov; June 27, 2022. https://clinicaltrials.gov/ct2/show/NCT04488866.

Southwest Oncology Group. A phase II trial of sacituzumab govitecan (IMMU-132) (NSC #82016) for patients with HER2-negative breast cancer and brain metastases. Clinical trial registration. clinicaltrials.gov; July 20, 2022. https://clinicaltrials.gov/ct2/show/NCT04647916.

Okajima D, Yasuda S, Maejima T, Karibe T, Sakurai K, Aida T, et al. Datopotamab deruxtecan, a novel TROP2-directed antibody-drug conjugate, demonstrates potent antitumor activity by efficient drug delivery to tumor cells. Mol Cancer Therapeut 2021 Dec 20(12):2329–40. https://doi.org/10.1158/1535-7163.MCT-21-0206 . Epub 2021 Aug 19.

Ocean AJ, Starodub AN, Bardia A, Vahdat LT, Isakoff SJ, Guzrino M, et al. Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: safety and pharmacokinetics. Cancer 2017 Oct 1;123(19):3843–54. https://doi.org/10.1002/cncr.30789.

Krop I, Juric D, Shimmiz T, Tolcher A, Spira A, Mokhbara T, et al. Datopotamab deruxtecan in advanced/metastatic HER2- breast cancer: results from the phase 1 TROPiC-PanTumor01 study [abstract]. In: Proceedings of the 2021 san antonio breast cancer symposium; 2021 Dec 7-10, vol. 82. San Antonio, TX. Philadelphia (PA): AACR; Cancer Res; 2021. https://doi.org/10.1158/1538-7445.SABCS21-GS1-05. 4 Suppl Abstract nr GS1-05.

AstraZeneca. A phase 3, open-label, randomised study of datopotamab deruxtecan (Dato-DXG) versus investigator’s choice of chemotherapy in patients who are not candidates for PD-1/PD-L1 inhibitor therapy in first-line locally recurrent inoperable or metastatic triple-negative breast cancer (TROPiC-Breast02). Clinical trial registration. clinicaltrials.gov; August 5, 2022. https://clinicaltrials.gov/ct2/show/NCT05374512.

McKenzie JA, Mbofung RM, Malu S, Zhang M, Ashkin E, Devi S, et al. The effect of taxane-based chemotherapy on overall survival in patients with hormone receptor-positive breast cancer. J Natl Cancer Inst 2018 Jan 1;110(7):777–86. https://doi.org/10.1093/jnci/djy257.